Jeannig Berrou

Paris, 75010, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications

Preclinical Evaluation of a Novel Small Molecule Inhibitor of LIM Kinases (LIMK) CEL_Amide in Philadelphia-Chromosome Positive (BCR::ABL+) Acute Lymphoblastic Leukemia (ALL).

Preclinical Evaluation of a Novel Small Molecule Inhibitor of LIM Kinases (LIMK) CEL_Amide in Philadelphia-Chromosome Positive (BCR::ABL+) Acute Lymphoblastic Leukemia (ALL).

Journal: Journal of clinical medicine
Published: October 17, 2022

A multiparametric niche-like drug screening platform in acute myeloid leukemia.

A multiparametric niche-like drug screening platform in acute myeloid leukemia.

Journal: Blood cancer journal
Published: November 30, 2021

Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia.

Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia.

Journal: Leukemia
Published: October 12, 2021

Biological Effects of BET Inhibition by OTX015 (MK-8628) and JQ1 in NPM1-Mutated (NPM1c) Acute Myeloid Leukemia (AML).

Biological Effects of BET Inhibition by OTX015 (MK-8628) and JQ1 in NPM1-Mutated (NPM1c) Acute Myeloid Leukemia (AML).

Journal: Biomedicines
Published: September 07, 2021

Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells.

Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells.

Journal: Leukemia research
Published: June 02, 2020

BET inhibitors impair leukemic stem cell function only in defined oncogenic subgroups of acute myeloid leukaemias.

BET inhibitors impair leukemic stem cell function only in defined oncogenic subgroups of acute myeloid leukaemias.

Journal: Leukemia research
Published: September 18, 2019

Natural Killer Lymphocytes Are Dysfunctional in Kidney Transplant Recipients on Diagnosis of Cancer.

Natural Killer Lymphocytes Are Dysfunctional in Kidney Transplant Recipients on Diagnosis of Cancer.

Journal: Transplantation
Published: January 23, 2016

BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells.

BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells.

Journal: Oncotarget
Published: November 26, 2014

Natural killer cell dysfunction in uremia: the role of oxidative stress and the effects of dialysis.

Natural killer cell dysfunction in uremia: the role of oxidative stress and the effects of dialysis.

Journal: Blood purification
Published: May 17, 2013

Natural killer cell function, an important target for infection and tumor protection, is impaired in type 2 diabetes.

Natural killer cell function, an important target for infection and tumor protection, is impaired in type 2 diabetes.

Journal: PloS one
Published: August 13, 2012
Showing 1-10 of 10

Last Updated: 09/26/2026